Table 6.
Pharmacokinetic characterization of 13a with iv and oral administration.
| 13a | 13a | Panobinostat93 | |
|---|---|---|---|
| Administered dose (mg/kg) | iv at 5 mg/kg | oral at 20 mg/kg | oral at 50 mg/kg |
| Cmax (ng/mL) | -- | 45.1 | 116 |
| t1/2 (h) | 15.2 | 7.45 | 2.9 |
| AUC0-inf (ng·h/mL) | 334 | 265 | 126 |
| F% | -- | 19.8 | 4.62 |
a
13a was injected via iv and oral (n = 3), blood was sampled at different time-points after dosing for 24 h, and the inhibitor plasma concentration is determined via LC-MS/MS. The area under the plasma concentration versus time curve (AUC) is calculated using the linear trapezoidal method. The PK data are fitted to obtain PK parameters using the non-compartmental method.